Telmisartan
Also known as: Micardis
Angiotensin II Receptor Blocker | Cardiac Protection On Cycle
Overview
Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery.
Key benefits
- Potent 24-hour blood pressure reduction with once-daily dosing
- Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
- Nephroprotection through reduced intraglomerular pressure and proteinuria
- Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
- No negative impact on exercise performance, VO2 max, or recovery
- Reduction of pathological vascular remodeling and arterial stiffness
- Longest half-life of all ARBs ensuring consistent 24-hour coverage
- Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Mechanism of action
Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.
Molecular data
- Type
- Benzimidazole derivative (C33H30N4O2)
- Half-life
- ~24 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cardiovascular Protection
Renal Protection
Metabolic Health
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 40-80 mg/day | Once daily | — |
| — | 20-40 mg/day | Once daily | — |
| — | 40-80 mg/day | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Dizziness or lightheadedness, particularly during the first few days or after dose increases
- Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
- Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
- Back pain and myalgia (uncommon but reported)
- Fatigue
Rare side effects
- Hyperkalemia (elevated potassium), particularly in patients with renal impairment, diabetes, or those taking potassium-sparing diuretics
- Angioedema (extremely rare with ARBs, far less common than with ACE inhibitors)
- Hepatotoxicity (rare case reports of elevated liver enzymes)
- Renal impairment in patients with bilateral renal artery stenosis or severe volume depletion
Contraindications
- Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
- Bilateral renal artery stenosis
- Known hypersensitivity to telmisartan or any excipients
- Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
- Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Monitoring
- Blood pressure: regular home monitoring recommended; clinical assessment at 2-4 weeks after initiation or dose change
- Serum potassium: at baseline and within 1-2 weeks of initiation, then periodically (especially if concurrent potassium supplements or potassium-sparing agents)
- Renal function (serum creatinine, eGFR): at baseline, within 1-2 weeks, then annually
- Basic metabolic panel: annually or more frequently in patients with renal impairment or diabetes
- Hematocrit (in AAS users): telmisartan does not affect erythropoiesis, but elevated hematocrit from AAS use compounds cardiovascular risk
References
Primary literature and clinical-trial data informing this entry.